Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Pilot Program for Compassionate Access System Gets Underway with Sanofi’s Cabazitaxel
May 7, 2014
- Joint Panel of Health, Science Ministries Wraps Up Talks on Ethics Code for Epidemiological, Clinical Research
May 2, 2014
- Topical Ketoprofen Contraindicated in Later Pregnancy: MHLW Safety Information
May 2, 2014
- Point-Based Calculations for Premiums Will Improve Predictability, Says Creator
May 1, 2014
- PAFSC’s Second Committee Backs Approval of Janssen, Sanofi Prostate Cancer Drugs
May 1, 2014
- PAFSC’s First Committee Recommends Approval for SGLT-2 Inhibitor Canaglu
April 30, 2014
- Kitasato Daiichi to Carry on with Delayed Quota in Flu Vaccine Project, but Slapped with Delinquency Charges
April 30, 2014
- Kaketsuken, Takeda Picked for Flu Vaccine Project to Fill BIKEN Quota
April 30, 2014
- MHLW Issues Notification Calling for Revision of Package Insert for Sanofi’s Benambax
April 30, 2014
- MHLW Bureaucrats Think Chuikyo Will Spurn Annual Drug Price Revisions, Again
April 28, 2014
- MHLW Should Present Its Own Proposal to Design Envisioned Mixed Care System: Panel Chair
April 28, 2014
- PMDA’s Preliminary Meetings, Face-to-Face Counseling Rise in FY2013
April 28, 2014
- Chuikyo Healthcare Provider Rep Vexed by Health Minister Proposal on Use of Drug Cost-Effective Assessment
April 25, 2014
- JMA Veep Nakagawa Fumes at Industry, Says “Application Lag” Elicited New Mixed Care Proposal
April 25, 2014
- Chuikyo Subcommittee OKs Point-Based Premium Calculation Method, Adoption Scheduled in May
April 24, 2014
- LDP Study Group to Call for Expansion of R&D Tax Credit System, Oppose Annual NHI Price Cuts
April 24, 2014
- PAFSC’s Second Committee to Discuss Janssen, Sanofi Prostate Cancer Drugs on April 30
April 23, 2014
- Public Knowledge-Based Applications Appropriate for Propranolol, Levonorgestrel: Panel
April 23, 2014
- Health Minister Wary about Annual Drug Price Cuts, but Aso, Amari Give Backing
April 23, 2014
- Min. Tamura Positive about Mixed Care Discussions with Govt Panel
April 22, 2014
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…